Compare LVO & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVO | CVM |
|---|---|---|
| Founded | 2009 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 30.6M |
| IPO Year | 2010 | 1996 |
| Metric | LVO | CVM |
|---|---|---|
| Price | $2.39 | $1.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.75 | ★ $12.50 |
| AVG Volume (30 Days) | 52.5K | ★ 167.4K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $77,144,000.00 | $264,033.00 |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $27.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $2.08 | $0.89 |
| 52 Week High | $7.19 | $7.80 |
| Indicator | LVO | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 37.89 |
| Support Level | $2.16 | $1.34 |
| Resistance Level | $5.83 | $1.52 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 39.10 | 20.29 |
LiveOne Inc creator-first, music, entertainment and technology platform focused on delivering premium experiences and content world-wide through paid users and live and virtual events. It is in the acquisition, distribution and monetization of live music events, Internet radio, podcasting/vodcasting and music-related membership, streaming and video content. It provide services through a dedicated over-the-top application powered by Slacker (LiveOne App) called LiveOne. The company has three operating segments, PodcastOne, Slacker and Media Group. The company generates majority of revenue from PodcastOne. Its operations are based in the United States. It generate revenue through the sale of paid user services and advertising from its music offerings, from the licensing, advertising.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.